The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Treatment of the Neuroleptic-Nonresponsive Schizophrenic Patient
Open accessAbstract
The treatment and management of neuroleptic-resistant schizophrenic patients, who comprise 5 to 25 percent of all patients with that diagnosis, are major problems for psychiatry. In addition, another large group of schizophrenic patients, perhaps 5 to 20 percent, are intolerant of therapeutic dosages of neuroleptic drugs because of extrapyramidal symptoms, including akathisia, parkinsonism, and tardive dyskinesia. Because about 60 percent of neuroleptic-resistant schizophrenic patients respond to clozapine and a large percentage of neuroleptic-intolerant patients are able to tolerate clozapine, it should be considered the treatment of choice for such patients until other therapies are proven to be superior. A trial of clozapine alone should usually be continued for up to 6 months before it is terminated or supplemental agents are tried. Plasma levels of clozapine may be useful to guide dosage. The major side effects of clozapine are granulocytopenia or agranulocytosis (1%-2%) and a dose-related increase in the incidence of generalized seizures. Psychosocial treatments such as education of the patient and the family about the nature of the illness, rehabilitation programs, social skills training, and assistance in housing are generally needed to obtain optimal benefit from clozapine, as with other somatic therapies. If clozapine is unavailable, unacceptable, or not tolerated, a variety of approaches may be employed to supplement typical antipsychotic drugs for patients who do not respond adequately to these agents alone. These include lithium; electroconvulsive therapy; carbamazepine or valproic acid; benzodiazepines; antidepressant drugs; reserpine; L-dopa and amphetamine; opioid drugs; calcium channel blockers; and miscellaneous other pharmacologic approaches. The evidence for the efficacy of these ancillary somatic therapies in treatment-resistant patients is relatively weak. Polypharmacy should be tried only for discrete periods and with clear goals. If these are not achieved, supplemental medications should be discontinued. Psychosurgery is not a recommended alternative at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
European Journal of Clinical Pharmacology
(2013) · European Journal of Clinical Pharmacology · doi:10.1007/228.1432-1041 · Cited by 608
ARCHIVES OF NEUROLOGY AND PSYCHIATRY
Mott, F. W. (1923) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-192304000-00071 · Cited by 576
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
Phenothiazine Treatment in Acute Schizophrenia: Effectiveness
(1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210028005 · Cited by 334
Treatment of psychiatric illness by stereotactic cingulotomy
Ballantine, H. T., Bouckoms, A. J., Thomas, E. K., & Giriunas, I. E. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90080-1 · Cited by 328
Dose equivalence of the anti-psychotic drugs
Davis, J. M. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90071-5 · Cited by 324
Important Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Dimensions of Outcome with Clozapine
Meltzer, H. Y. (1992) · British Journal of Psychiatry · doi:10.1192/s000712500029692x · Cited by 252
Self-citationClozapine: neuroleptic-induced EPS and tardive dyskinesia
Casey, D. E. (1989) · Psychopharmacology · doi:10.1007/bf00442559 · Cited by 251
Braude, W. M., Barnes, T. R. E., & Gore, S. M. (1983) · British Journal of Psychiatry · doi:10.1192/bjp.143.2.139 · Cited by 249
Lindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
Neuroleptics : neurochemical, behavioral, and clinical perspectives
Coyle, J. T., & Enna, S. J. (1983) · Raven Press eBooks · Cited by 231
Studies of Depressive Symptoms in Schizophrenia
Johnson, D. A. W. (1981) · British Journal of Psychiatry · doi:10.1192/bjp.139.2.89 · Cited by 219
Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists.
Gould, R. J., Murphy, K. M., Reynolds, I. J., & Snyder, S. H. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.16.5122 · Cited by 218
HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia
Lieberman, J. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220061007 · Cited by 207
Integrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., Wegner, J. T., & Lieberman, J. A. (1986) · PubMed · Cited by 207
Effect of phenytoin on plasma clozapine concentrations in two patients.
Preskorn, S. H., & Fast, G. A. (1991) · PubMed · Cited by 201
Gerlach, J., Koppelhus, P., Helweg, E., & Monrad, A. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb09706.x · Cited by 197
A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten, T. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200062009 · Cited by 188
Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age
Häring, C., Meise, U., Humpel, C., Saria, A., Fleischhacker, W. W., & Hinterhuber, H. (1989) · Psychopharmacology · doi:10.1007/bf00442557 · Cited by 182
Costs and Benefits of Two Doses of Fluphenazine
Marder, S. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220015002 · Cited by 182
Drug Intelligence and Clinical Pharmacy
Francke, D. E. (1969) · Drug Intelligence & Clinical Pharmacy · doi:10.1177/106002806900300601 · Cited by 172
Effect of clozapine on human serum prolactin levels
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.12.1550 · Cited by 171
Anticonvulsants in affective disorders
Emrich, H. M., 大熊, 輝., & Müller, A. A. (1984) · Excerpta Medica eBooks · Cited by 165
Bindra, J. S., & Lednicer, D. (1982) · American Chemical Society eBooks · Cited by 149
Adjunctive Imipramine in the Treatment of Postpsychotic Depression
Siris, S. G. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180043008 · Cited by 149
Plasma Level Monitoring of Antipsychotic Drugs Clinical Utility
Dahl, S. G. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611010-00003 · Cited by 147
Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer, M. S., Vogel, W. H., DiJohnson, C., Dewey, D. A., Sheves, P., Cavicchia, S., Little, P., Schmidt, R., & Kimes, I. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810100064012 · Cited by 144
The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia
Meltzer, H. Y., Sommers, A., & Luchins, D. J. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198612000-00002 · Cited by 143
Self-citationGrohmann, R., R�ther, E., Sassim, N., & Schmidt, L. G. (1989) · Psychopharmacology · doi:10.1007/bf00442571 · Cited by 136
Chemotherapy in psychiatry : principles and practice
Baldessarini, R. J. (1985) · Medical Entomology and Zoology · Cited by 135
Dissimilar dosing with high-potency and low-potency neuroleptics
Baldessarini, R. J., Katz, B., & Cotton, P. G. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.6.748 · Cited by 131
Treatment of Secondary Depression in Schizophrenia
Prusoff, B. A. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780050079010 · Cited by 130
Chemotherapy in Psychiatry: Principles and Practice
Seelye, E. E. (1986) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1986.40.4.614 · Cited by 129
Effects of Carbamazepine on Plasma Haloperidol Levels
Jann, M. W., Ereshefsky, L., Saklad, S. R., Seidel, D. R., Davis, C. M., BURCH, N. R., & Bowden, C. L. (1985) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198504000-00010 · Cited by 124
CARBAMAZEPINE IN TREATMENT OF VIOLENT SCHIZOPHRENICS
Hakola, H. P. A., & Laulumaa, V. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92423-0 · Cited by 120
Behavioral effects of l-Dopa in schizophrenic patients
ANGRIST, B. M., Sathananthan, G., & Gershon, S. (1973) · Psychopharmacology · doi:10.1007/bf00429294 · Cited by 119
Small, J. G., Milstein, V., Marhenke, J. D., et al. (1987) · PubMed · Cited by 117
Incidence of tardive dyskinesia: five-year data from a prospective study.
Kane, J. M., Woerner, M. G., Weinhold, P., Wegner, J. T., Kinon, B. J., & Borenstein, M. (1984) · PubMed · Cited by 111
Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients
GOFF, D. C., Brotman, A. W., WAITES, M., & Mccormick, S. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.4.492 · Cited by 110
The effect of l-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs
Gerlach, J., & L�hdorf, K. (1975) · Psychopharmacology · doi:10.1007/bf00421193 · Cited by 110
Apparent Neuroleptic Malignant Syndrome with Clozapine and Lithium
Pope, H. G., Cole, J. O., Choras, P., & Fulwiler, C. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198608000-00010 · Cited by 109
Mechanisms of Clozapine†-Induced Agranulocytosis
Gerson, S. L., & Meltzer, H. Y. (1992) · Drug Safety · doi:10.2165/00002018-199200071-00007 · Cited by 107
Self-citationPsychosocial Treatment: Individual, Group, Family, and Community Support Approaches
Mosher, L. R., & Keith, S. J. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.10 · Cited by 107
Clozapine: New research on efficacy and mechanism of action
Meltzer, H. Y., Bastani, B., Ramirez, L. F., & Matsubara, S. (1989) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00449814 · Cited by 106
Self-citationClinical pharmacokinetics of clozapine in chronic schizophrenic patients
Cheng, Y. F., Lundberg, T., Bondesson, U., Lindstr�m, L. H., & Gabrielsson, J. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf01046700 · Cited by 101
Fluphenazine Dose, Clinical Response, and Extrapyramidal Symptoms During Acute Treatment
Levinson, D. F. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200069010 · Cited by 97
Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients
Wolkowitz, O. M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310072009 · Cited by 93
Family Management in Schizophrenia
(1982) · New England Journal of Medicine · doi:10.1056/nejm198211043071921 · Cited by 93
Prevalence and severity of akathisia in patients on clozapine
Cohen, B. M., Keck, P. E., Satlin, A., & Cole, J. O. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90329-k · Cited by 91
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Valproate in the Treatment of Acute Mania
Holtzer, C. D., & Echaves, S. A. (1996) · Journal of Pharmacy Technology · doi:10.1177/875512259601200104 · Cited by 91
Clinical studies of the endogenous opioid system.
Pickar, D., Cohen, M. R., Набер, Д., & Cohen, R. M. (1982) · PubMed · Cited by 90
Vm, N. (1983) · PubMed · Cited by 87
Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia
Kidron, R., Averbuch, I., Klein, E., & Belmaker, R. H. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90087-3 · Cited by 79
Clinical use of the antipsychotics
Kessler, K., & Waletzky, J. P. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.2.202 · Cited by 79
The Pharmacologic Treatment of Schizophrenia: A Progress Report
Donaldson, S. R., Gelenberg, A. J., & Baldessarini, R. J. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.4.504 · Cited by 76
Carbamazepine as an adjunct of antipsychotic therapy
Dose, M., Apelt, S., & Emrich, H. M. (1987) · Psychiatry Research · doi:10.1016/0165-1781(87)90109-0 · Cited by 74
Ekblom, B., & Häggström, J. E. (1974) · PubMed · Cited by 70
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia
Wolkowitz, O. M., Pickar, D., Doran, A. R., Breier, A. F., Tarell, J., & Paul, S. M. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.85 · Cited by 70
Clozapine-induced neuroleptic malignant syndrome.
Dasgupta, K., & Young, A. S. (1991) · PubMed · Cited by 67
Effect of clozapine in severe tardive dyskinesia: a case report.
Meltzer, H. Y., & Luchins, D. J. (1984) · PubMed · Cited by 67
Self-citationPrediction of Neuroleptic-Induced Dystonia
Keepers, G. A., & Casey, D. E. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198710000-00011 · Cited by 63
Commentary: Defining Treatment Refractoriness in Schizophrenia
Meltzer, H. Y. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.563 · Cited by 60
Self-citation5.4. Brief Psychiatric Rating Scale (BPRS)
(1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb10905.x · Cited by 60
Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects
Keepers, G. A., & Casey, D. E. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.1.85 · Cited by 58
Gäebel, W., & Pietzcker, A. (1985) · Pharmacopsychiatry · doi:10.1055/s-2007-1017372 · Cited by 58
Carbamazepine in violent non-epileptic schizophrenics.
Dj, L. (1984) · PubMed · Cited by 56
Karson, C. N., Weinberger, D. R., Bigelow, L. B., & Wyatt, R. J. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.12.1627 · Cited by 55
Thyrotropin-releasing hormone in schizophrenia
Davis, K. L., Hossister, L. E., & Berger, P. A. (1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.9.951 · Cited by 55
A case of clozapine-induced neuroleptic malignant syndrome.
Miller, D. D., Sharafuddin, M. J., & Kathol, R. G. (1991) · PubMed · Cited by 55
Wæhrens, J., & Gerlach, J. (1980) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1980.tb00882.x · Cited by 54
Differential response to amphetamine in schizophrenia
Cesarec, Z., & Nyman, A. K. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb05066.x · Cited by 53
Ceruletide for schizophrenia: A double-blind study
Mattes, J. A., Hom, W., Rochford, J. M., & Orlosky, M. J. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90024-1 · Cited by 52
CARBAMAZEPINE FOR THE VIOLENT PSYCHIATRIC PATIENT
LUCHINS, D. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92052-4 · Cited by 51
The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
Bucci, L. (1987) · Psychopharmacology · doi:10.1007/bf00690936 · Cited by 49
Chlorpromazine and reserpine in the treatment of psychoses
Kinross‐Wright, V. (1955) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1955.tb42464.x · Cited by 46
TREATMENT OF CHRONIC SCHIZOPHRENIC REACTIONS WITH RESERPINE
Hollister, L. E., Krieger, G., Kringel, A., & Roberts, R. H. (1955) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1955.tb42455.x · Cited by 46
Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia
Holden, J., Itil, T. M., Keskiner, A., & Fixk, M. (1968) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(68)80059-8 · Cited by 46
Neuroleptic malignant syndrome associated with clozapine use.
Anderson, E. S., & Powers, P. S. (1991) · PubMed · Cited by 45
The combined use of neuroleptics and ECT in drug resistant schizophrenic patients.
Friedel, R. O. (1986) · PubMed · Cited by 45
Simpson, G. M., Branchey, M. H., & Shrivastava, R. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92749-5 · Cited by 44
Gujavarty, K. S., Greenberg, L. B., & Fink, M. (1987) · PubMed · Cited by 41
Lithium Combined with Haloperidol in Schizophrenic Patients
Lerner, Y., Mintzer, Y., & Schestatzky, M. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.3.359 · Cited by 40
Treatment of Medically Intractable Mental Disease by Limited Frontal Leucotomy — Justifiable?
Sweet, W. H. (1973) · New England Journal of Medicine · doi:10.1056/nejm197311222892105 · Cited by 39
Novel approaches to the pharmacotherapy of schizophrenia
Meltzer, H. Y. (1986) · Drug Development Research · doi:10.1002/ddr.430090105 · Cited by 39
Self-citationTreatment of catatonia with low-dose lorazepam
Greenfeld, D. A., Conrad, C., Kincare, P., & Bowers, M. B. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1224 · Cited by 37
Viloxazine and the Depressed Schizophrenic—Methodological Issues
Kurland, A. A., & NAGARAJU, A. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb01730.x · Cited by 34
Carbamazepine Maintenance Treatment in Outpatient Schizophrenics
Carpenter, W. T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250071010 · Cited by 33
Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study
Altamura, A. C., Mauri, M. C., Mantero, M., & Brunetti, M. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02942.x · Cited by 30
A high-dose, double-blind study of ceruletide in the treatment of schizophrenia
Mattes, J. A., Hom, W., & Rochford, J. M. (1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.12.1482 · Cited by 30
Ko, G. N., Korpi, E. R., Freed, W. J., Zalcman, S. J., & Bigelow, L. B. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90085-x · Cited by 28
Repeated naloxone administration in schizophrenia: A phase II world health organization study
Pickar, D., Bunney, W. E., Douillet, P., Sethi, B. B., Sharma, M., Vartanian, M. E., Rr, L., Naber, D., Leibl, K., Yamashita, I., et al. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90197-2 · Cited by 28
Combined Reserpine-Chlorpromazine in Treatment of Disturbed Psychotics
BARSA, J. A. (1955) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1955.02330150046006 · Cited by 26
Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
STEDMAN, T. J., Whiteford, H., Eyles, D. W., Welham, J., & Pond, S. M. (1991) · PubMed · Cited by 25
Development of the Clozaril Patient Management System
Bastani, B., Alphs, L. D., & Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442576 · Cited by 24
Self-citationEffect of L‐Dopa in Schizophrenia
Inanaga, K., Inoue, K., Tachibana, H., et al. (1972) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1972.tb01119.x · Cited by 24
Efficacy of Adjunctive Carbamazepine in the Treatment of Chronic Schizophrenia
Herrera, J. M., Sramek, J. J., & COSTA, J. F. (1987) · Annals of Pharmacotherapy · doi:10.1177/106002808702100411 · Cited by 24
Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients
Robertson, A. G., Berry, R. S., & Meltzer, H. Y. (1982) · Psychopharmacology · doi:10.1007/bf00428168 · Cited by 14
Self-citationCLINICAL, PSYCHOLOGICAL AND MYONEURAL CHANGES IN PSYCHOTIC PATIENTS UNDER ORAL SERPASIL MEDICATION
Finn, M. H. P., NADOLSKI, F., Guy, W., & Gross, M. S. (1955) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-195511000-00007 · Cited by 11
THE PLACE OF RESERPINE IN THE TREATMENT OF THE CHRONIC PSYCHOTIC PATIENT
Gore, C., EGAN, G. P., & Walton, D. (1957) · American Journal of Psychiatry · doi:10.1176/ajp.114.4.333 · Cited by 9
Clonazepam in the treatment of chronic schizophrenia
Raines, J. M., & Greenspan, D. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.11.1510a · Cited by 5
Cited by
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Self-citationBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Dopamine receptors and brain function
Jaber, M., Robinson, S. W., Missale, C., & Caron, M. G. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00100-1 · Cited by 570
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 513
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436
Metadata
- Authors
- Meltzer, H. Y.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-01-01
- Volume
- 18
- Issue
- 3
- Pages
- 515-542
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2133602373
- Cited by
- 332
- References
- 105
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.